Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MILK-GDM Semaglutide study
PACTR202607841254199Phase 4Not yet recruiting
- Sponsor
- Infectious Diseases Institute
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of semaglutide in gestational diabetes mellitus (GDM), sponsored by Infectious Diseases Institute. Primary endpoints: Maternal plasma and breastmilk semaglutide steady-state concentrations, Infant plasma semaglutide concentrations and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
03
Conditions
gestational diabetes mellitus (GDM)
Beyond the preview
Go deeper on PACTR202607841254199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202607841254199.